VRTX Buyback

Veritex Holdings, Inc Buyback

OLI recorded this information on 12/12/2019

Company:

Veritex Holdings, Inc

Buyback:

VRTX buyback

$Amount Authorized:

$175,000,000

Buyback Details:

The Board of Directors (the "Board") of Veritex Holdings, Inc. (Nasdaq: VBTX) (the "Company") authorized an increase and extension of its stock buyback program (the "Stock Buyback Program") pursuant to which the Company may, from time to time, purchase shares of its outstanding common stock. The Stock Buyback Program authorized the Company to purchase up to $100.0 million of its outstanding common stock and that amount has been increased by the Board to $175.0 million. The Board also authorized an extension of the expiration date of the Stock Buyback Program from August 31, 2020 to December 31, 2020. The shares may be repurchased in the open market or in privately negotiated transactions from time to time, depending upon market conditions and other factors, and in accordance with applicable regulations of the Securities and Exchange Commission (the "SEC"). The Stock Buyback Program does not obligate the Company to purchase any shares and may be terminated or amended by the Board at any time prior to its expiration date. As of December 12, 2019, the Company had repurchased $94.6 million, or 3,802,711 shares, of its common stock through the Stock Buyback Program.

Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

Vertex Pharmaceuticals SEC Filing Email Alerts Service

Open the VRTX Page at The Online Investor »

VRTX — Key Stats (updated Fri., May. 3, 10:29 AM)

Company Name:	Vertex Pharmaceuticals, Inc.
Stock buyback:	VRTX buyback
Website:	www.vrtx.com
Sector:	Drugs & Pharmaceuticals
Number of ETFs Holding VRTX:	122
Total Market Value Held by ETFs:	$15.39B
Total Market Capitalization:	$103.88B
% of Market Cap. Held by ETFs:	14.81%

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.

Veritex Holdings, Inc Buyback

VRTX Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved